Life Sciences Partners (LSP) has announced that, following approval by the shareholders of both companies, the merger between its portfolio companies Kiadis and Celmed has completed. The merger creates Kiadis Pharma BV, an oncology drug development company with four products in various stages of clinical development and a valuable pipeline of early drug candidates. Both Kiadis and Celmed have previously received financial backing from LSP.
EMZ recently opened its first international office in Munich, headed by partner Klaus Maurer
Fund deploys tickets of €1-5m in seed and series-A rounds to support European B2B SaaS startups
French GP is planning to take exclusive control of the fire safety specialist
Insight, Deutsche Telekom Capital Partners, Capnamic and Iris Capital also participate